Solid Biosciences Inc

The stock remains in a Stage 2 advancing uptrend with a pronounced Parabola acceleration but is now extremely overbought and extended, elevating Stage Transition Risk. Medium-term bias stays bullish, yet short-term timing is unfavorable; execution should be deferred until a pullback into the EMAs or prior support area, where buying on support can be considered.

• ↑$180M cash runway through Q2 2024 funds SGT001/SGT003 development
• ↑SGT001 trial delivers durable efficacy in nine-dose cohort
• ↓EPS loss of $0.52 highlights deep unprofitability and cash burn